marijuana stock news

Aurora Cannabis, Analysts Review and Target Price, Recent Partner Collaborations

Aurora has positioned itself to be a significant supplier of the growing demand for medical and legal recreational in Canada and other parts of the world. The company continues to experience increasing patient count, and German exports continue to drive the overall revenue and margins up.

Aurora Recorded $11.7 million in revenues, up 201% from Q2 2017 and up 41.8% sequentially from Q1 2018. The company is also sitting on significant cash in hand and is looking for ways to raise more to maintain growth momentum and expand overall capacity.

The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as ”Aurora Mountain,” and a second 40,000 square foot high-technology production facility known as ”Aurora Vie” in Pointe-Claire, Quebec on Montreal’s West Island. In January 2018, Aurora’s 800,000 square foot flagship cultivation facility, Aurora Sky, located at the Edmonton International Airport, was licensed. Once at full capacity, Aurora Sky is expected to produce over 100,000 kg per annum of cannabis.


Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the ”Author”) and is fact checked and reviewed by a third-party research service company (the ”Reviewer”) represented by a chartered financial analyst, for further information on analyst credentials, please email Vikas Agrawal, a CFA® charter holder (the ”Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 |
Leave a Reply

Your email address will not be published.

You May Also Like

$PZOO holly Owned Subsidiary, CannabisKing Distribution, LLC Signs Deal

Pazoo Wholly Owned Subsidiary, CannabisKing Distribution, LLC Signs Deal To Distribute MJPayment…

Organigram Holdings Inc. (OGRMF) invests in Hyasynth Biologicals Inc.

Organigram invests in Hyasynth Biologicals Inc., helps bring transformative “cellular agriculture” to…

Tilray, Inc. (TLRY) Announces Launch of New Medical Cannabis Brand, Symbios

Tilray Announces Launch of New Medical Cannabis Brand, Symbios Tilray, Inc. (“Tilray”)…

Lexaria Bioscience Corp. (LXRP) Files New Patent Application

Lexaria Files New Patent Application Lexaria Bioscience Corp. (LXRP)(CSE:LXX) (the “Company” or…